CM/TNS/24/5713 - NHS Framework for Transition products - 1 February 2025
Who
| Buyer | NHS England — not a council we hold |
| Supplier | Baxter Healthcare Ltd |
| Supplier | Biocon |
| Supplier | Dr.Reddy's Laboratories (UK) Limited |
| Supplier | Sun Pharma UK Ltd |
| Supplier | Thornton and Ross Ltd |
| Supplier | Zentiva Pharma UK Ltd |
What
Project title: NHS National Framework for Transition products commencing 1 February 2025 Offer reference number: CM/TNS/24/5713 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5713/01 - Eribulin Injection, Bosutinib Tablets and Liraglutide Injection Lot 1 CESW: 01/02/2025 to 31/05/2026 (16 months) Lot 2 LSNE: 01/02/2025 to 31/05/2026 (16 months) Lot 3 NWLN: 01/02/2025 to 31/05/2026 (16 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Dates and source
| Runs | 1 Feb 2025 to 31 May 2026 |
| OCID | ocds-b5fd17-e85a5f73-1208-4e45-a159-08011aef8a18 |
| Notice | Read it on Contracts Finder |
Figures are as published An award value in OCDS may be a framework ceiling rather than a sum anyone expects to spend, so a large figure here is not evidence of a large purchase.